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BAG-1 is a recently identiﬁed Bcl-2-interacting anti-apoptotic protein. The aim of our study was to investigate the
immunohistochemical staining pattern of BAG-1 protein in patients with colorectal cancer and examine associations of BAG-1
expression with various clinicopathological factors and patient survival. Tumour samples were collected from 86 patients
diagnosed with colorectal cancer. There was signiﬁcant variation in the immunohistochemical staining patterns for BAG-1,
including absent staining and staining of either the cytoplasm, nucleus or both. Twenty-one colorectal carcinomas (24.4%)
exhibited a nuclear staining pattern whilst 56 (65.1%) exhibited cytoplasmic staining. The percentage of cases exhibiting
nuclear BAG-1 positivity was signiﬁcantly higher in distant metastasis-positive cases (55.6%) than in distant metastasis-negative
cases (20.8%; P=0.036). Overall survival was signiﬁcantly shorter for patients with tumours exhibiting BAG-1 positive nuclei
than those with absent nuclear BAG-1-staining (P=0.011). In addition, the multivariate cox proportional hazard models
indicated that nuclear BAG-1 expression was the only independent prognostic variable for mortality (P=0.013). These studies
demonstrate that nuclear BAG-1 expression is a useful predictive factor for distant metastasis and a poor prognosis in patients
with colorectal cancer.
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Recent studies have suggested that apoptosis is controlled by a
variety of genes, with dysregulation of these genes playing an
important role in the pathogenesis of many human diseases includ-
ing cancer (Oltvai et al, 1993; Soini et al, 1996; Koshida et al,
1997). BAG-1 protein was originally identiﬁed as a novel regulator
of apoptosis by virtue of its ability to bind Bcl-2, a potent inhibitor
of cell death, and it not only independently inhibits apoptosis but
also enhances the anti-apoptotic activity of Bcl-2 (Takayama et al,
1995). Moreover, variations in BAG-1 levels parallel alterations in
cellular proliferation and viability (Clevenger et al, 1997). Despite
extensive studies of the function of BAG-1, the exact role of
BAG-1 in the carcinogenesis and progression of human colorectal
cancers remains unclear. In addition, discrepant results regarding
BAG-1 immunostaining and patient survival in early breast cancer
have been in dispute (Tang et al, 1999; Turner et al, 2001). In the
present study, we used a polyclonal antibody that allowed speciﬁc
detection of human BAG-1 protein and examined the immunohis-
tochemical staining patterns of BAG-1 protein in patients with
colorectal cancer. We also determined associations between the
BAG-1 expression pattern and various clinicopathological factors
and patient survival.
MATERIALS AND METHODS
Patients and tumour samples
A total of 86 adenocarcinomas of the colon and rectum were
studied. Tumours were obtained surgically between 1991 and
1995 at the Department of Surgery II, Oita Medical University.
All specimens were ﬁxed in 10% buffered formalin and embedded
in parafﬁn.
Immunohistochemical staining
Deparafﬁnized and rehydrated specimens were heated in 10 mM
citrate buffer, pH 6.0, for 10 min in an autoclave at 1218C. After
treatment with 10% normal goat serum for 10 min to block
nonspeciﬁc protein binding, polyclonal BAG-1 antibody (rabbit
antimouse, clone C-16; Santa Cruz CA, USA; 250 X dilution)
was applied. Tissue sections were incubated overnight at 48C.
After brief rinsing, the Catalyzed Signal Ampliﬁcation system
(DAKO Corp.) was used according to the manufacturer’s instruc-
tions to visualise speciﬁc BAG-1 staining. After brief washing,
sections were incubated with diaminobenzidine and H2O2 for
5 min. Sections were then lightly counterstained with haematoxy-
lin, dehydrated in graded alcohols, cleared in xylene and
coverslipped.
The immunopositive cell area was used for evaluation of the
immunohistochemical staining of BAG-1 antibody: negative 0–
10%; positive 410%. Expression of BAG-1 was also evaluated in
terms of immunostaining of the tumour cell nucleus and cyto-
plasm. A clinicopathological study was performed by reference to
mean tumour diameter, depth of invasion, histological grade of
adenocarcinoma and the presence of lymph node or distant metas-
tasis.
Statistical analysis
Correlations between antigen expression and the various clinico-
pathological factors (mean tumour diameter, depth of invasion,
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node or distant metastasis) were examined by the Student’s t-test,
chi-squared test, Fisher’s exact probability or Mann–Whitney’s U-
test. Overall survival was calculated according to the Kaplan–
Meier method, from the time of operation to either death or date
of last follow-up, and the log-rank test was used to determine
statistical differences between life tables. The multivariate cox
proportional hazards model was used to determine whether any
of the factors tested (tumour diameter, depth of invasion, histolo-
gical grade of adenocarcinoma, lymph node metastasis and nuclear
or cytoplasmic immunohistochemical expression for BAG-1) could
be identiﬁed as independent prognostic factors for overall patient
survival. A P value of less than 0.05 was considered statistically
signiﬁcant.
RESULTS
Immunohistochemical staining of BAG-1
There was signiﬁcant variation in the immunohistochemical stain-
ing patterns of BAG-1 with tumours exhibiting absent staining and
staining of either the cytoplasm, nucleus or both. The distinction
between cytoplasmic and nuclear BAG-1 staining is demonstrated
in Figure 1A,B. Twenty-one colorectal carcinomas (24.4%) exhib-
ited a nuclear staining pattern whilst 56 (65.1%) exhibited a
cytoplasmic staining pattern.
Correlations between the expression of BAG-1 and the
various clinicopathological factors
Table 1 shows the correlations between the expression of BAG-1
and various clinicopathological factors. The percentage of tumours
exhibiting nuclear BAG-1 positivity was signiﬁcantly higher in cases
positive for distant metastases (55.6%) compared to cases without
distant metastases (20.8%; P=0.036; Fisher’s exact probability). No
other signiﬁcant correlation was evident between nuclear or cyto-
plasmic BAG-1 expression and the various clinicopathological
factors analysed.
Survival analysis
Overall survival, as determined by the Kaplan–Meier analysis, was
signiﬁcantly shorter for patients with tumours exhibiting nuclear
BAG-1 positivity compared to those that were negative for nuclear
BAG-1 staining (Figure 2A; log-rank test, P=0.011). Survival at 5
years was 51.3% in patients with tumours exhibiting nuclear
BAG-1 positivity compared to 83.9% in those patients with
tumours that were negative for nuclear BAG-1 staining. There
was no signiﬁcant difference in survival between patients with cyto-
plasmic BAG-1-positive tumours and those with cytoplasmic BAG-
1-negative tumours (Figure 2B; log-rank test, P=0.955). Using the
variables of tumour diameter, depth of invasion, histological grade
of adenocarcinoma, lymph node metastasis, nuclear BAG-1 expres-
sion and cytoplasmic BAG-1 expression, the multivariate cox
proportional hazard model indicated that nuclear BAG-1 expres-
sion was the only independent prognostic variable for mortality
(Table 2: hazard ratio=3.572, P=0.013). The other clinicopathologi-
cal factors were not signiﬁcantly associated with patient survival.
DISCUSSION
There have been few reports regarding the immunohistochemical
staining pattern of BAG-1 in colorectal cancer. Immunohistochem-
ical expression of BAG-1 detectable by antibody (C-16) staining is
weak in colorectal mucosa (Takayama et al, 1998). Use of the stan-
dard avidin–biotin–peroxidase complex (ABC) technique that we
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Figure 1 Immunolocalisation of BAG-1 in samples of human colorectal
carcinomas. Immunostaining revealed BAG-1 is immunostained in the tu-
mour cell nucleus (A) and the cytoplasm (B: Original magniﬁcation 6400).
Table 1 Correlation between the expression of BAG-1 and clinico-
pathologic factors
Nuclear staining
pattern
Cytoplasmic
staining pattern
Positive P value Positive P value
rate (%) rate (%)
Mean of diameter 48.0/45.0 0.56a 47.4/42.6 0.29a
(positive/negative; mm)
Depth of invasion
T1 22.2 0.97b 66.7 0.67b
T2 26.1 69.6
T3 24.1 63.0
Histological grade of adenocarcinoma
Well differentiated 28.2 0.58b 61.5 0.45b
Moderately differentiated 20.5 65.9
Poorly differentiated 33.3 100.0
Lymph node metastasis
positive 26.5 0.72c 58.8 0.32c
negative 23.1 69.2
Distant metastasis
positive 55.6 0.036d 55.6 0.82d
negative 20.8 66.2
a: Student’s t-test, b: Mann–Whitney’s U-test, c: Chi-square test, d: Fisher’s exact
probability.
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5% of colorectal cancer cells exhibit nuclear or cytoplasmic positiv-
ity (data not shown). Hence, we used the Catalyzed Signal
Ampliﬁcation system (DAKO Corp.), which is an extremely sensi-
tive immunocytochemical visualisation system to facilitate the
accurate determination of the expression of BAG-1 in colorectal
cancers. Indeed, this is the ﬁrst large-scale retrospective study to
assess the prognostic signiﬁcance of BAG-1 expression in patients
with colorectal cancer. We noted that tumour cells exhibited two
patterns of immunohistochemical staining viz cytoplasmic or
nuclear. Comparable cytoplasmic or nuclear staining patterns have
been reported in other cancers (Brimmell et al, 1999; Tang et al,
1999; Yamauchi et al, 2001). The reason is as follows: the bag-1
gene of humans and mice can produce two major proteins as a
result of alternative translation initiation sites in a common
mRNA. The shorter isoform (BAG-1) is predominantly a cytoplas-
mic protein, while the longer isoform (BAG-1L) is mostly
translocated to the nucleus through its nuclear localisation signal
(Packham et al, 1997; Takayama et al, 1998). The BAG-1 antibody
(C-16) used in this study should recognise all isoforms (Crocoll et
al, 2000). In addition, the intracellular localisation of BAG-1 may
be modulated by cellular conditions or the differentiation status
of these epithelial cells (Yamauchi et al, 2001). As a result, the
BAG-1 protein may be immunolocalised to the cytoplasm or
nucleus in colorectal cancer cells.
There are several reports to indicate that the expression of BAG-
1 correlates with the malignant potential of other carcinomas
(Tang et al, 1999; Shindoh et al, 2000). We then studied the rela-
tionship between BAG-1 expression and clinicopathological factors
and prognosis. The nuclear expression of BAG-1 correlated with
the presence of distant metastases. In addition, the prognosis of
patients with nuclear BAG-1-positive tumours was signiﬁcantly
worse than that of those with nuclear BAG-1-negative tumours.
In contrast, the cytoplasmic expression of BAG-1 was not related
to the clinicopathological factors examined or patient prognosis.
Therefore, the nuclear expression of BAG-1 was impressively corre-
lated with the malignant potential in colorectal cancer. BAG-1 has
been reported to facilitate epithelial cell survival following detach-
ment from the underlying extracellular matrix (Ruoslahti, 1996;
Weaver et al, 1996) and to promote cell migration in human
gastric cancer cells (Naishiro et al, 1999). These functions could
contribute to the development of distant metastases in malignant
tumours since the overexpression of BAG-1 in melanoma cells
increases the metastatic potential of these tumour cells (Takaoka
et al, 1997). In our study, the percentage of cases exhibiting nuclear
BAG-1 positivity was signiﬁcantly higher in distant metastasis-posi-
tive cases than in distant metastasis-negative cases. Previous studies
have reported that the gain-of-function p53 mutants derive from
human tumours upregulated the transcription of BAG-1 RNA
and the expression of a reporter gene from the BAG-1 promoter
(Yang et al, 1999). These data are very interesting, since the func-
tion of BAG-1 may be associated with carcinogenesis or malignant
potential acting through mutant-p53 functions. In summary, we
can conclude that nuclear BAG-1 expression is an indicator of
malignant potential and is a poor prognostic marker in colorectal
carcinoma.
Finally, we discuss the signiﬁcance of the nuclear BAG-1 expres-
sion. The shorter BAG-1 isoform is predominantly a cytoplasmic
protein, while the longer isoform (BAG-1L) is mostly translocated
to the nucleus (Packham et al, 1997; Takayama et al, 1998). More-
over, BAG-1L protein is rarely expressed in normal tissues but is
commonly expressed by tumour cell lines, and a change in BAG-
1 mRNA translation frequently accompanies malignant transforma-
tion (Takayama et al, 1998). In short, the nuclear BAG-1
expression almost certainly indicates BAG-1L, and is likely to be
relevant to the malignant potential. Interestingly, several studies
have reported that nuclear BAG-1 expression correlated with
reduced survival in patients with invasive breast cancer (Tang et
al, 1999) and laryngeal cancer after radiation therapy (Yamauchi
et al, 2001). Thus, it is reasonable to suppose that nuclear BAG-
1 expression is closely related to the malignant potential. However,
two papers reported that cytoplasmic BAG-1 expression repre-
sented a potential marker of improved survival in early-stage
breast cancer patients (Turner et al, 2001) and nonsmall cell lung
cancer patients (Rorke et al, 2001) whilst nuclear BAG-1 expression
was not related to the malignant potential. It is likely that the
discrepancy between results may be attributed to different antibody
or organ speciﬁcity. We believe that it is not clear whether the
discrepant results are in conﬂict, since the differences of BAG-1
localisation in cancer cells indicate different expression of BAG-1
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Figure 2 Overall survival probability in relation to nuclear (A) and cytoplasm (B) BAG-1 expression status.
Table 2 Multivariate analysis of prognostic factors
Relative 95%
risk for Conﬁdence
Variable P value mortality interval
Diameter 0.903 1.063 0.349–2.532
Depth of Invasion 0.183 0.411 0.111–1.524
Histological grade of adenocarcinoma 0.465 0.686 0.249–1.887
Lymph node metastasis 0.259 1.800 0.648–5.000
Nuclear BAG-1 expression 0.013 3.572 1.306–9.773
Cytoplasmic BAG-1 expression 0.770 0.846 0.275–2.601
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data strongly indicate that further studies are necessary in order
to clarify the relationship between BAG-1 isoforms and BAG-1
functions.
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